Cribstone Capital Management LLC boosted its position in Allergan PLC. (NYSE:AGN) by 0.7% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,848 shares of the company’s stock after buying an additional 45 shares during the period. Cribstone Capital Management LLC’s holdings in Allergan PLC. were worth $1,665,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Israel Discount Bank of New York purchased a new position in Allergan PLC. during the first quarter worth approximately $988,000. Trust Co. of Vermont boosted its position in Allergan PLC. by 62.8% in the first quarter. Trust Co. of Vermont now owns 2,875 shares of the company’s stock worth $687,000 after buying an additional 1,109 shares during the last quarter. Capital Planning Advisors LLC boosted its position in Allergan PLC. by 79.3% in the first quarter. Capital Planning Advisors LLC now owns 3,674 shares of the company’s stock worth $878,000 after buying an additional 1,625 shares during the last quarter. BKD Wealth Advisors LLC purchased a new position in Allergan PLC. during the first quarter worth approximately $219,000. Finally, First Long Island Investors LLC purchased a new position in Allergan PLC. during the first quarter worth approximately $4,826,000. 83.63% of the stock is currently owned by institutional investors and hedge funds.
Allergan PLC. (NYSE AGN) traded down 0.35% during trading on Friday, hitting $223.99. 2,006,235 shares of the stock traded hands. The stock has a market cap of $74.88 billion, a PE ratio of 6.82 and a beta of 1.16. The company has a 50-day moving average price of $243.31 and a 200 day moving average price of $238.68. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80.
Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. During the same period in the prior year, the company posted $3.35 earnings per share. The business’s revenue for the quarter was up 8.8% compared to the same quarter last year. Analysts expect that Allergan PLC. will post $16.27 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be paid a dividend of $0.70 per share. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 annualized dividend and a yield of 1.25%. Allergan PLC.’s dividend payout ratio is currently 9.95%.
COPYRIGHT VIOLATION NOTICE: “Cribstone Capital Management LLC Purchases 45 Shares of Allergan PLC. (NYSE:AGN)” was published by BNB Daily and is the property of of BNB Daily. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.baseball-news-blog.com/2017/08/19/allergan-plc-nyseagn-position-boosted-by-cribstone-capital-management-llc-updated-updated-updated.html.
A number of research analysts have recently commented on AGN shares. Cowen and Company set a $400.00 target price on shares of Allergan PLC. and gave the stock a “buy” rating in a research report on Thursday, June 8th. Sanford C. Bernstein reissued an “outperform” rating on shares of Allergan PLC. in a research report on Thursday, May 25th. Mizuho reduced their target price on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating on the stock in a research report on Friday, June 9th. Cantor Fitzgerald started coverage on shares of Allergan PLC. in a research report on Friday, June 16th. They set a “neutral” rating and a $231.00 target price on the stock. Finally, Zacks Investment Research raised shares of Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 target price on the stock in a research report on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have assigned a buy rating to the stock. Allergan PLC. presently has an average rating of “Buy” and a consensus price target of $275.49.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.